Introduction to Outcome-Based Risk Sharing Agreements

Understand opportunities and constraints with risk sharing agreements

18 Apr 2023

2 days course

English

12,600 DKK ex VAT
(app. 1,694 EUR ex VAT)
50% DISCOUNT FOR PUBLIC INSTITUTIONS

Summary

Is a different approach to pricing agreements between pharma and payers the path to introduction of new, innovative medicine? What problem do we solve with outcome-based risk sharing agreements and what is the perspective for patients, the public sector, and the pharma industry respectively?

Outcome-based risk sharing agreements are not a new phenomenon. Yet innovative pricing is still quite rare, among other because of a high level of complexity and limited experiences.

Get the required knowledge to assess if innovative pricing is the path towards market introduction for your product. When does it make sense?

Gain insight into the various types of outcome-based risk sharing agreements, learn about the experiences that already exist and get to know where to find data and how you can set up an outcome-based risk sharing agreement.

The course builds on the Danish market, but we also cover the rest of Scandinavia and discuss risk sharing agreements in a national and global perspective.

ANNIVERSARY OFFER:

Book any course* scheduled for a date in 2022 and bring a colleague along: 2 for the price of 1. Only valid for bookings made 2 May until 16 May.

Sign up yourself and a colleague in the same order form – then we make sure only one course fee is charged.

(*Networks and courses offered together with University of Copenhagen and CBS are not included.)

    Key words

    • Outcome-based pricing agreement
    • RSA (risk sharing agreements)
    • Innovative pricing
    • RWD/real world data
    • Market access
    • Medical affairs
    Read more

    Course leader(s) & Lecturer(s)

    • Tove Holm-Larsen
      Course leader
      CEO
      Pharmaevidence
    • Niels Christian Hirsch
      Course leader
      Chefrådgiver
      DLI Market Intelligence ApS
    See all

    IS THIS COURSE FOR YOU?

    This course is relevant for you if you work in Market Access, Commercial or Medical Affairs or in Clinical project development.

    What you will learn

    1. Understand the thinking behind outcome-based risk sharing agreements
    2. Understand how to put a price on risk in various constellations of public-private collaboration
    3. Get an overview of where to find data for outcome-based risk sharing agreements
    4. Understand the concern of the public system and the pharma industry respectively

    What your company will get

    1. An employee who understands the national and global perspectives in outcome-based risk sharing agreements
    2. An employee who knows about the different types of outcome-based risk sharing agreements
    3. An employee who knows where to find data for the outcome-based risk sharing agreements
    4. An employee who knows about the management of risk sharing agreements in Scandinavia

    Course calendar

    Starting 18 Apr 2023
    18 Apr 2023 9:00-16:00

    day 1

    • Light breakfast and networking
    • Outcome-based risk sharing agreements - which problem are we trying to solve?
    • Outcome-based risk sharing agreements - which problem are we trying to solve, as seen from the patient?
    • Outcome-based risk sharing agreements - which problem are we trying to solve, as seen from the public perspective?
    • Lunch and networking
    • Helicopter view: Presentation of the Danish system
    • Different types of outcome-based risk sharing agreements
    • Nordic overview: How do they work with outcome-based risk sharing agreements in the other Scandinavian countries? 
    19 Apr 2023 9:00-16:00

    Day 2

    • Light breakfast and networking
    • Panel discussion: What is Pharma’s perspective on outcome-based risk sharing agreements on a national and global level?
    • Presentation of a real case implementation in Denmark
    • Lunch and networking
    • Presentation of model simulations from the Danish OSCAR project
    • Where can you find relevant data and how do you get access to them?
    • Wrap up and evaluation
    Practical information

    Registration

    Registration deadline
    18 Apr 2023
    Atrium
    Lersø Parkallé 101
    2100 København Ø
    Register
    18 - 19 Apr
    Sometimes things change. This is the expected programme.

    Course information

    Literature

    Life Science Insights’ report, executive summary. Download the report here

    Prerequisites

    Min. 3 years’ experience in Market Access, Medical Affairs or Commercial within Pharma.

    Examination

    There is no examination for this course.

    The course is part of the Market Access diploma programme

    Course leader(s)

    Tove Holm-Larsen
    CEO
    Pharmaevidence
    Niels Christian Hirsch
    Chefrådgiver
    DLI Market Intelligence ApS

    You may also be interested in these courses

    WANT TO KNOW MORE or need help?

    Contact Contact Client Manager Ida Salicath at +45 39 15 09 46

    Send me a message